<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>About 10%-15% of patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> develop <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This is considered a <z:e sem="disease" ids="C0032927" disease_type="Neoplastic Process" abbrv="">premalignant condition</z:e> because it can progress from <z:mpath ids='MPATH_160'>metaplasia</z:mpath> to high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and eventually to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, major advances have been made in the endoscopic treatment of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, therefore limiting the role of surgery in the treatment of this disease </plain></SENT>
</text></document>